UBS Downgrades Janux Therapeutics to Neutral, Lowers Price Target to $15
Benzinga Newsdesk 6 months ago
NewsDowngradesPrice TargetAnalyst Ratings
UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers the price target from $57 to $15.
UBS analyst David Dai downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Neutral and lowers the price target from $57 to $15.